Literature DB >> 33847515

Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens.

Stephanie A Harmon1, William Gesztes1, Denise Young1, Sherif Mehralivand1, Yolanda McKinney1, Thomas Sanford1, Jonathan Sackett1, Jennifer Cullen1, Inger L Rosner1, Shiv Srivastava1, Maria J Merino1, Bradford J Wood1, Peter A Pinto1, Peter L Choyke1, Albert Dobi1, Isabell A Sesterhenn1, Baris Turkbey1.   

Abstract

Background Although prostate MRI is routinely used for the detection and staging of localized prostate cancer, imaging-based assessment and targeted molecular sampling for risk stratification are an active area of research. Purpose To evaluate features of preoperative MRI and MRI-guided biopsy immunohistochemistry (IHC) findings associated with biochemical recurrence (BCR) of prostate cancer after surgery. Materials and Methods In this retrospective case-control study, patients underwent multiparametric MRI before MRI-guided biopsy followed by radical prostatectomy between 2008 and 2016. Lesions were retrospectively scored with the Prostate Imaging Reporting and Data System (PI-RADS) (version 2) by radiologists who were blinded to the clinical-pathologic results. The IHC staining, including stains for the ETS-related gene, phosphatase and tensin homolog, androgen receptor, prostate specific antigen, and p53, was performed with targeted biopsy specimens of the index lesion (highest suspicion at MRI and pathologic grade) and scored by pathologists who were blinded to clinical-pathologic outcomes. Cox proportional hazards regression analysis was used to evaluate associations with recurrence-free survival (RFS). Results The median RFS was 31.7 months (range, 1-101 months) for 39 patients (median age, 62 years; age range, 47-76 years) without BCR and 14.6 months (range, 1-61 months) for 40 patients (median age, 59 years; age range, 47-73 years) with BCR. MRI features that showed a significant relationship with the RFS interval included an index lesion with a PI-RADS score of 5 (hazard ratio [HR], 2.10; 95% CI: 1.05, 4.21; P = .04); index lesion burden, defined as ratio of index lesion volume to prostate volume (HR, 1.55; 95% CI: 1.2, 2.1; P = .003); and suspicion of extraprostatic extension (EPE) (HR, 2.18; 95% CI: 1.1, 4.2; P = .02). Presurgical multivariable analysis indicated that suspicion of EPE at MRI (adjusted HR, 2.19; 95% CI: 1.1, 4.3; P = .02) and p53 stain intensity (adjusted HR, 2.22; 95% CI: 1.0, 4.7; P = .04) were significantly associated with RFS. Conclusion MRI features, including Prostate Imaging Reporting and Data System score, index lesion burden, extraprostatic extension, and preoperative guided biopsy p53 immunohistochemistry stain intensity are associated with biochemical relapse of prostate cancer after surgery. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Costa in this issue.

Entities:  

Mesh:

Year:  2021        PMID: 33847515      PMCID: PMC8165944          DOI: 10.1148/radiol.2021202425

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   29.146


  28 in total

Review 1.  PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway.

Authors:  Anwar R Padhani; Jelle Barentsz; Geert Villeirs; Andrew B Rosenkrantz; Daniel J Margolis; Baris Turkbey; Harriet C Thoeny; François Cornud; Masoom A Haider; Katarzyna J Macura; Clare M Tempany; Sadhna Verma; Jeffrey C Weinreb
Journal:  Radiology       Date:  2019-06-11       Impact factor: 11.105

2.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Authors:  James L Mohler; Emmanuel S Antonarakis; Andrew J Armstrong; Anthony V D'Amico; Brian J Davis; Tanya Dorff; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric Mark Horwitz; Michael Hurwitz; Joseph E Ippolito; Christopher J Kane; Michael R Kuettel; Joshua M Lang; Jesse McKenney; George Netto; David F Penson; Elizabeth R Plimack; Julio M Pow-Sang; Thomas J Pugh; Sylvia Richey; Mack Roach; Stan Rosenfeld; Edward Schaeffer; Ahmad Shabsigh; Eric J Small; Daniel E Spratt; Sandy Srinivas; Jonathan Tward; Dorothy A Shead; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2019-05-01       Impact factor: 11.908

3.  Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma.

Authors:  Neema Jamshidi; Daniel J Margolis; Steven Raman; Jiaoti Huang; Robert E Reiter; Michael D Kuo
Journal:  Radiology       Date:  2017-04-28       Impact factor: 11.105

4.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome.

Authors:  Gyorgy Petrovics; Aijun Liu; Syed Shaheduzzaman; Bungo Furusato; Bungo Furasato; Chen Sun; Yongmei Chen; Martin Nau; Lakshmi Ravindranath; Yidong Chen; Albert Dobi; Vasantha Srikantan; Isabell A Sesterhenn; David G McLeod; Maryanne Vahey; Judd W Moul; Shiv Srivastava
Journal:  Oncogene       Date:  2005-05-26       Impact factor: 9.867

5.  p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.

Authors:  G L Griewe; R C Dean; W Zhang; D Young; I A Sesterhenn; N Shanmugam; D G McLeod; J W Moul; S Srivastava
Journal:  Prostate Cancer Prostatic Dis       Date:  2003       Impact factor: 5.554

6.  A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI.

Authors:  Sherif Mehralivand; Joanna H Shih; Stephanie Harmon; Clayton Smith; Jonathan Bloom; Marcin Czarniecki; Samuel Gold; Graham Hale; Kareem Rayn; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Radiology       Date:  2019-01-22       Impact factor: 11.105

7.  Prostate Cancer: Utility of Whole-Lesion Apparent Diffusion Coefficient Metrics for Prediction of Biochemical Recurrence After Radical Prostatectomy.

Authors:  Andrew B Rosenkrantz; Justin M Ream; Paul Nolan; Henry Rusinek; Fang-Ming Deng; Samir S Taneja
Journal:  AJR Am J Roentgenol       Date:  2015-12       Impact factor: 3.959

8.  ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.

Authors:  B Furusato; S-H Tan; D Young; A Dobi; C Sun; A A Mohamed; R Thangapazham; Y Chen; G McMaster; T Sreenath; G Petrovics; D G McLeod; S Srivastava; I A Sesterhenn
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-06-29       Impact factor: 5.554

9.  Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Authors:  David A Quigley; Ha X Dang; Shuang G Zhao; Paul Lloyd; Rahul Aggarwal; Joshi J Alumkal; Adam Foye; Vishal Kothari; Marc D Perry; Adina M Bailey; Denise Playdle; Travis J Barnard; Li Zhang; Jin Zhang; Jack F Youngren; Marcin P Cieslik; Abhijit Parolia; Tomasz M Beer; George Thomas; Kim N Chi; Martin Gleave; Nathan A Lack; Amina Zoubeidi; Robert E Reiter; Matthew B Rettig; Owen Witte; Charles J Ryan; Lawrence Fong; Won Kim; Terence Friedlander; Jonathan Chou; Haolong Li; Rajdeep Das; Hui Li; Ruhollah Moussavi-Baygi; Hani Goodarzi; Luke A Gilbert; Primo N Lara; Christopher P Evans; Theodore C Goldstein; Joshua M Stuart; Scott A Tomlins; Daniel E Spratt; R Keira Cheetham; Donavan T Cheng; Kyle Farh; Julian S Gehring; Jörg Hakenberg; Arnold Liao; Philip G Febbo; John Shon; Brad Sickler; Serafim Batzoglou; Karen E Knudsen; Housheng H He; Jiaoti Huang; Alexander W Wyatt; Scott M Dehm; Alan Ashworth; Arul M Chinnaiyan; Christopher A Maher; Eric J Small; Felix Y Feng
Journal:  Cell       Date:  2018-07-19       Impact factor: 41.582

10.  MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Authors:  Veeru Kasivisvanathan; Antti S Rannikko; Marcelo Borghi; Valeria Panebianco; Lance A Mynderse; Markku H Vaarala; Alberto Briganti; Lars Budäus; Giles Hellawell; Richard G Hindley; Monique J Roobol; Scott Eggener; Maneesh Ghei; Arnauld Villers; Franck Bladou; Geert M Villeirs; Jaspal Virdi; Silvan Boxler; Grégoire Robert; Paras B Singh; Wulphert Venderink; Boris A Hadaschik; Alain Ruffion; Jim C Hu; Daniel Margolis; Sébastien Crouzet; Laurence Klotz; Samir S Taneja; Peter Pinto; Inderbir Gill; Clare Allen; Francesco Giganti; Alex Freeman; Stephen Morris; Shonit Punwani; Norman R Williams; Chris Brew-Graves; Jonathan Deeks; Yemisi Takwoingi; Mark Emberton; Caroline M Moore
Journal:  N Engl J Med       Date:  2018-03-18       Impact factor: 176.079

View more
  2 in total

Review 1.  The role of MRI in prostate cancer: current and future directions.

Authors:  Maria Clara Fernandes; Onur Yildirim; Sungmin Woo; Hebert Alberto Vargas; Hedvig Hricak
Journal:  MAGMA       Date:  2022-03-16       Impact factor: 2.533

2.  E-Cadherin, Integrin Alpha2 (Cd49b), and Transferrin Receptor-1 (Tfr1) Are Promising Immunohistochemical Markers of Selected Adverse Pathological Features in Patients Treated with Radical Prostatectomy.

Authors:  Piotr Zapała; Łukasz Fus; Zbigniew Lewandowski; Karolina Garbas; Łukasz Zapała; Barbara Górnicka; Piotr Radziszewski
Journal:  J Clin Med       Date:  2021-11-27       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.